Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 7—July 2019
Research

Asymptomatic Dengue Virus Infections, Cambodia, 2012–2013

Sowath Ly1, Camille Fortas1, Veasna Duong, Tarik Benmarhnia, Anavaj Sakuntabhai, Richard Paul, Rekol Huy, Sopheak Sorn, Kunthy Nguon, Siam Chan, Souv Kimsan, Sivuth Ong, Kim Srorn Kim, Sowathy Buoy, Lim Voeung, Philippe Dussart, Philippe Buchy12, and Arnaud Tarantola1Comments to Author 
Author affiliations: Institut Pasteur du Cambodge, Phnom Penh, Cambodia (S. Ly, C. Fortas, V. Duong, S. Sorn, K. Nguon, S. Chan, S. Kimsan, S. Ong, P. Dussart, P. Buchy, A. Tarantola); University of California, San Diego, California, USA (T. Benmarhnia); Institut Pasteur, Paris, France (A. Sakuntabhai, R. Paul); Malaria National Center, Phnom Penh (R. Huy); Kampong Cham Provincial Hospital, Kampong Cham, Cambodia (K.S. Kim); Prey Chhor District Referral Hospital, Kampong Cham (S. Buoy); Tboung Khmum District Referral Hospital, Thoung Khmum, Cambodia (L. Voeung)

Main Article

Table 1

Surveillance data from perifocal investigations for asymptomatic dengue virus, Cambodia, 2012–2013*

Surveillance data
 2012
 2013
 Total
No. participants 2,391 5,569 7,960
No. villages investigated 35 77 104
No. perifocal investigations conducted 47 102 149
Mean no. participants per perifocal investigation
 51
 55
 53
Confirmed infections, no. (%) 88 258 346
Strictly asymptomatic 5 (5.7) 21 (8.1) 26 (7.5)
Afebrile 33 (37.5) 77 (29.8) 110 (31.2)
Symptomatic
 83 (94.3)
 237 (91.9)
 320 (92.5)
Attack rate/1,000 participants, % 36.8 46.3 43.5
Asymptomatic infections 2.1 3.8 3.3
Symptomatic infections 34.7 42.6 40.2
Afebrile infections
 13.8
 13.8
 13.8
Symptoms at diagnosis or follow-up, no. (%) 83 237 320
Fever 55 (66.2) 180 (75.9) 236 (73.8)
Headache 52 (62.7) 169 (71.3) 221 (69.1)
Muscle pain 16 (19.3) 73 (30.8) 89 (27.8)
Retro-orbital pain 17 (20.5) 73 (30.8) 90 (28.1)
Joint pain 17 (20.5) 68 (28.7) 85 (26.5)
Rash 15 (18.1) 53 (22.4) 68 (21.3)
Any bleeding
 13 (15.7)
 50 (21.1)
 63 (19.7)
Hospitalizations, no. (%)
 3 (3.5)
 8 (3.3)
 11 (3.3)
DENV infections 88 258 346
Serotype, no. (%)
DENV-1 82 (98.8) 188 (72.9) 270 (78.0)
DENV-2 1 (1.2) 36 (13.9) 37 (10.7)
DENV-3 0 2 (0.8) 2 (0.6)
DENV-4 0 31 (12.0) 31 (9.0)
DENV-1 and DENV-2 0 1 (0.4) 1 (0.3)
Missing 5 0 5

*Participants 0.5–30 years of age in 2012 and 0.5–20 years of age in 2013. DENV, dengue virus.

Main Article

1These authors contributed equally to this article.

2Current affiliation: GlaxoSmithKline Vaccines Research and Design, Singapore.

Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external